特発性肺線維症の世界市場レポート 2025年

特発性肺線維症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.0％で57億4,000万米ドルに成長します。予測期間の成長は、研究開発の拡大、精密医療アプローチ、疾患罹患率の増加、バイオマーカー開発の進歩、政府のイニシアティブ、資金調達に起因します。予測期間の主な動向には、診断技術の進歩、標的療法の出現、遠隔医療と遠隔モニタリング、併用療法、肺移植の進歩などが含まれます。

特発性肺線維症市場は、主に線維性疾患の有病率の増加によって成長する態勢にあります。これらの疾患は、様々な臓器における線維性結合組織の異常な蓄積によって特徴付けられ、線維化関連のシグナル伝達経路を標的とする特発性肺線維症（IPF）薬剤による治療を受けています。特に、米国肺協会は2022年12月に、米国では約20万7000人が罹患しており、年間約5万8000人が新たにIPFと診断されたと報告しています。この疾患は男性に多く、50歳以上の高齢者に多く発症することから、特発性肺線維症市場を牽引する線維性疾患の拡大が重要な役割を担っていることが明らかになった。

老年人口の増加は、今後の特発性肺線維症（IPF）市場拡大の原動力になると予測されています。老年人口は、特定の社会やコミュニティ内の高齢者で構成されます。加齢は肺の構造的・機能的変化と関連しており、IPFのような呼吸器疾患に対する高齢者の脆弱性を高めています。この加齢に関連した感受性は、IPF治療に対する需要の高まりに寄与しています。例えば、米国に本部を置く保健専門機関である世界保健機関（WHO）は2022年10月、2030年までに世界の6人に1人が60歳以上になると報告し、この年齢層の人口は2050年までに21億人に達すると予測しています。その結果、老人人口の増加が特発性肺線維症市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界特発性肺線維症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の特発性肺線維症市場：成長率分析
• 世界の特発性肺線維症市場の実績：規模と成長, 2019-2024
• 世界の特発性肺線維症市場の予測：規模と成長, 2024-2029, 2034F
• 世界特発性肺線維症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の特発性肺線維症市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニンテダニブ
• ピルフェニドン
• その他の薬物の種類
• 世界の特発性肺線維症市場作用機序別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗線維化剤
• チロシンキナーゼ阻害剤
• その他の作用機序
• 世界の特発性肺線維症市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 世界の特発性肺線維症市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンラインプロバイダー
• 世界の特発性肺線維症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• その他のエンドユーザー
• 世界の特発性肺線維症市場ニンテダニブのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 適応症
• 剤形
• 投与経路
• 世界の特発性肺線維症市場、ピルフェニドンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 適応症
• 剤形
• 投与経路
• 世界の特発性肺線維症市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 特定のエージェントまたはクラス
• 新たな治療法
• 併用療法

第7章 地域別・国別分析

• 世界の特発性肺線維症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の特発性肺線維症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 特発性肺線維症市場：競合情勢
• 特発性肺線維症市場：企業プロファイル
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Gilead Sciences Inc.
• Toray Industries Inc.
• Boehringer Ingelheim International GmbH
• Viatris Inc.
• Sun Pharmaceutical Industries Limited
• Shionogi and Co. Ltd.
• Cipla Inc.
• Zydus Lifesciences Ltd.
• Chong Kun Dang Pharmaceutical Corp.
• Kyorin Pharmaceutical Co. Ltd.
• Galapagos NV
• Veracyte Inc.
• Genentech Inc.
• FibroGen Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 特発性肺線維症市場2029：新たな機会を提供する国
• 特発性肺線維症市場2029：新たな機会を提供するセグメント
• 特発性肺線維症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by the gradual and continuous deterioration of the tissue surrounding the air sacs, known as alveoli, in the lungs. This condition results in the accumulation of scar tissue (fibrosis) within the lungs, hindering the efficient transfer of oxygen into the bloodstream.

The main types of drugs used in the treatment of idiopathic pulmonary fibrosis include nintedanib, pirfenidone, and others. Nintedanib is a medication prescribed for the treatment of specific lung conditions, including idiopathic pulmonary fibrosis (IPF), which is an interstitial lung disease with a progressive phenotype, and interstitial lung disease associated with systemic sclerosis. These drugs operate through various modes of action, such as antifibrotic agents and tyrosine kinase inhibitors, and can be administered through various routes, including oral and parenteral. Distribution channels for these medications include hospital pharmacies, retail pharmacies, and online platforms, serving various end users such as hospitals, clinics, and others.

The idiopathic pulmonary fibrosis market research report is one of a series of new reports from The Business Research Company that provides idiopathic pulmonary fibrosis market statistics, including idiopathic pulmonary fibrosis industry global market size, regional shares, competitors with idiopathic pulmonary fibrosis market share, detailed idiopathic pulmonary fibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the idiopathic pulmonary fibrosis industry. This idiopathic pulmonary fibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $4.15 billion in 2024 to $4.39 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing aging population, limited treatment options, rising disease awareness, healthcare infrastructure development

The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to expanded research and development, precision medicine approach, increasing disease incidence, advancements in biomarker development, government initiatives and funding. Major trends in the forecast period include advancements in diagnostic techniques, emergence of targeted therapies, telemedicine and remote monitoring, combination therapies, advancements in lung transplantation.

The idiopathic pulmonary fibrosis market is poised for growth, primarily driven by the increasing prevalence of fibrotic diseases. These conditions, marked by the abnormal accumulation of fibrous connective tissue in various organs, receive treatment through idiopathic pulmonary fibrosis (IPF) drugs targeting fibrosis-related signaling pathways. Notably, the American Lung Association reported in December 2022 that around 207,000 individuals in the United States were affected, with approximately 58,000 new IPF cases diagnosed annually. This condition, more prevalent in men and predominantly affecting those aged over 50, underscores the significant role of escalating fibrotic diseases in driving the idiopathic pulmonary fibrosis market.

The growing geriatric population is anticipated to drive the expansion of the idiopathic pulmonary fibrosis (IPF) market in the future. The geriatric population consists of elderly individuals within a specific society or community. Aging is linked to both structural and functional changes in the lungs, which increase the vulnerability of older adults to respiratory diseases like IPF. This age-related susceptibility contributes to the rising demand for IPF treatments. For example, in October 2022, the World Health Organization, a specialized health agency based in the US, reported that by 2030, 1 in 6 people globally will be aged 60 or older, with the number of individuals in this age group expected to reach 2.1 billion by 2050. Consequently, the increasing geriatric population is propelling the growth of the idiopathic pulmonary fibrosis market.

A notable trend gaining momentum in the idiopathic pulmonary fibrosis market is product innovation. Major companies in the industry are placing emphasis on developing innovative products to strengthen their market positions and gain a competitive advantage. For instance, in May 2022, Sandoz, a Swiss-based pharmaceutical company, introduced a generic version of pirfenidone, the first AB-rated equivalent to Genentech's Esbriet, for treating idiopathic pulmonary fibrosis. This generic medication, accessible through specialty pharmacies, offers eligible patients the benefit of a USD 0 co-pay program.

Companies in the idiopathic pulmonary fibrosis market are directing their efforts toward innovative products such as anti-fibrotic small-molecule inhibitors to sustain their market positions. These inhibitors, designed to target and inhibit fibrotic processes in the body, represent a significant advancement. In June 2023, Insilico Medicine, a US-based biotechnology company, initiated Phase II clinical trials for INS018_055, the world's first anti-fibrotic small molecule inhibitor designed through generative artificial intelligence. This groundbreaking approach utilizing AI in drug discovery showcases the potential for progress in idiopathic pulmonary fibrosis treatment.

In October 2022, AbbVie Inc., a US-based pharmaceutical company, acquired DJS Antibodies Ltd., a UK-based biotechnology company specializing in the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. This acquisition aims to enhance AbbVie's antibody research capabilities and expand its immunology portfolio.

Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the idiopathic pulmonary fibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The idiopathic pulmonary fibrosis (IPF) market consists of sales of anti-inflammatory, MAPK inhibitors, autotoxin inhibitors and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Idiopathic Pulmonary Fibrosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on idiopathic pulmonary fibrosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for idiopathic pulmonary fibrosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The idiopathic pulmonary fibrosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Nintedanib; Pirfenidone; Other Drug Types
• 2) By Mode Of Action: Antifibrotic Agents; Tyrosine Kinase Inhibitors; Other Modes Of Action
• 3) By Route Of Administration: Oral; Parenteral
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Providers
• 5) By End Users: Hospitals And Clinics; Other End Users
• Subsegments:
• 1) By Nintedanib: Indications; Dosage Forms; Administration Routes
• 2) By Pirfenidone: Indications; Dosage Forms; Administration Routes
• 3) By Other Drug Types: Specific Agents Or Classes; Emerging Therapies; Combination Therapies
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Idiopathic Pulmonary Fibrosis Market Characteristics

3. Idiopathic Pulmonary Fibrosis Market Trends And Strategies

4. Idiopathic Pulmonary Fibrosis Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Idiopathic Pulmonary Fibrosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Idiopathic Pulmonary Fibrosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Idiopathic Pulmonary Fibrosis Market Growth Rate Analysis
• 5.4. Global Idiopathic Pulmonary Fibrosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Idiopathic Pulmonary Fibrosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Idiopathic Pulmonary Fibrosis Total Addressable Market (TAM)

6. Idiopathic Pulmonary Fibrosis Market Segmentation

• 6.1. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nintedanib
• Pirfenidone
• Other Drug Types
• 6.2. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antifibrotic Agents
• Tyrosine Kinase Inhibitors
• Other Modes Of Action
• 6.3. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.4. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Providers
• 6.5. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Other End Users
• 6.6. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Nintedanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Indications
• Dosage Forms
• Administration Routes
• 6.7. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Pirfenidone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Indications
• Dosage Forms
• Administration Routes
• 6.8. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Specific Agents Or Classes
• Emerging Therapies
• Combination Therapies

7. Idiopathic Pulmonary Fibrosis Market Regional And Country Analysis

• 7.1. Global Idiopathic Pulmonary Fibrosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Idiopathic Pulmonary Fibrosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Idiopathic Pulmonary Fibrosis Market

• 8.1. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Idiopathic Pulmonary Fibrosis Market

• 9.1. China Idiopathic Pulmonary Fibrosis Market Overview
• 9.2. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Idiopathic Pulmonary Fibrosis Market

• 10.1. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Idiopathic Pulmonary Fibrosis Market

• 11.1. Japan Idiopathic Pulmonary Fibrosis Market Overview
• 11.2. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Idiopathic Pulmonary Fibrosis Market

• 12.1. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Idiopathic Pulmonary Fibrosis Market

• 13.1. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Idiopathic Pulmonary Fibrosis Market

• 14.1. South Korea Idiopathic Pulmonary Fibrosis Market Overview
• 14.2. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Idiopathic Pulmonary Fibrosis Market

• 15.1. Western Europe Idiopathic Pulmonary Fibrosis Market Overview
• 15.2. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Idiopathic Pulmonary Fibrosis Market

• 16.1. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Idiopathic Pulmonary Fibrosis Market

• 17.1. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Idiopathic Pulmonary Fibrosis Market

• 18.1. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Idiopathic Pulmonary Fibrosis Market

• 19.1. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Idiopathic Pulmonary Fibrosis Market

• 20.1. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Idiopathic Pulmonary Fibrosis Market

• 21.1. Eastern Europe Idiopathic Pulmonary Fibrosis Market Overview
• 21.2. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Idiopathic Pulmonary Fibrosis Market

• 22.1. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Idiopathic Pulmonary Fibrosis Market

• 23.1. North America Idiopathic Pulmonary Fibrosis Market Overview
• 23.2. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Idiopathic Pulmonary Fibrosis Market

• 24.1. USA Idiopathic Pulmonary Fibrosis Market Overview
• 24.2. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Idiopathic Pulmonary Fibrosis Market

• 25.1. Canada Idiopathic Pulmonary Fibrosis Market Overview
• 25.2. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Idiopathic Pulmonary Fibrosis Market

• 26.1. South America Idiopathic Pulmonary Fibrosis Market Overview
• 26.2. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Idiopathic Pulmonary Fibrosis Market

• 27.1. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Idiopathic Pulmonary Fibrosis Market

• 28.1. Middle East Idiopathic Pulmonary Fibrosis Market Overview
• 28.2. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Idiopathic Pulmonary Fibrosis Market

• 29.1. Africa Idiopathic Pulmonary Fibrosis Market Overview
• 29.2. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Idiopathic Pulmonary Fibrosis Market Competitive Landscape And Company Profiles

• 30.1. Idiopathic Pulmonary Fibrosis Market Competitive Landscape
• 30.2. Idiopathic Pulmonary Fibrosis Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Idiopathic Pulmonary Fibrosis Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Gilead Sciences Inc.
• 31.3. Toray Industries Inc.
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Viatris Inc.
• 31.6. Sun Pharmaceutical Industries Limited
• 31.7. Shionogi and Co. Ltd.
• 31.8. Cipla Inc.
• 31.9. Zydus Lifesciences Ltd.
• 31.10. Chong Kun Dang Pharmaceutical Corp.
• 31.11. Kyorin Pharmaceutical Co. Ltd.
• 31.12. Galapagos NV
• 31.13. Veracyte Inc.
• 31.14. Genentech Inc.
• 31.15. FibroGen Inc.

32. Global Idiopathic Pulmonary Fibrosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Idiopathic Pulmonary Fibrosis Market

34. Recent Developments In The Idiopathic Pulmonary Fibrosis Market

35. Idiopathic Pulmonary Fibrosis Market High Potential Countries, Segments and Strategies

• 35.1 Idiopathic Pulmonary Fibrosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Idiopathic Pulmonary Fibrosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Idiopathic Pulmonary Fibrosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer